The primary agenda is to consider and evaluate proposals for raising funds through one or more permissible modes, subject to statutory and regulatory approvals. The specific modes mentioned include:
- Preferential Issue (including preferential allotment of equity shares and/or convertible securities)
- Rights Issue
- Any other permissible mode or combination thereof
The Board will consider these options in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws.
The Board may also consider and transact any other business placed before it with the permission of the Chairman.
In accordance with the Company's Code of Conduct for Prevention of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities has been closed for all designated persons and their immediate relatives effective from 23rd June, 2026. The trading window will remain closed until 48 hours after the declaration of the outcome of the Board Meeting.
The outcome of the Board Meeting will be intimated to the Stock Exchange in accordance with applicable SEBI Listing Regulations.
The disclosure is signed by Mrs. Chaitali Kalpataru Shah, Director & CFO (DIN: 11167778), on behalf of Bacil Pharma Limited.